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Strain fidelity of chronic wasting disease upon murine adaptation
Abstract
Chronic wasting disease (CWD), a prion disease of deer and elk, is highly prevalent in some regions of
North America. The establishment of mouse-adapted CWD prions has proven difficult due to the strong
species barrier between mice and deer. Here we report the efficient transmission of CWD to transgenic
mice overexpressing murine PrP. All mice developed disease 500 +/- 62 days after intracerebral CWD
challenge. The incubation period decreased to 228 +/- 103 days on secondary passage and to 162 +/- 6
days on tertiary passage. Mice developed very large, radially structured cerebral amyloid plaques similar
to those of CWD-infected deer and elk. PrP(Sc) was detected in spleen, indicating that murine CWD
was lymphotropic. PrP(Sc) glycoform profiles maintained a predominantly diglycosylated PrP pattern,
as seen with CWD in deer and elk, across all passages. Therefore, all pathological, biochemical, and
histological strain characteristics of CWD appear to persist upon repetitive serial passage through mice.
These findings indicate that the salient strain-specific properties of CWD are encoded by agent-intrinsic
components rather than by host factors.
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Chronic wasting disease (CWD), a prion disease of deer and elk, is highly prevalent in some regions of North
America. The establishment of mouse-adapted CWD prions has proven difficult due to the strong species
barrier between mice and deer. Here we report the efficient transmission of CWD to transgenic mice overex-
pressing murine PrP. All mice developed disease 500  62 days after intracerebral CWD challenge. The
incubation period decreased to 228  103 days on secondary passage and to 162  6 days on tertiary passage.
Mice developed very large, radially structured cerebral amyloid plaques similar to those of CWD-infected deer
and elk. PrPSc was detected in spleen, indicating that murine CWD was lymphotropic. PrPSc glycoform profiles
maintained a predominantly diglycosylated PrP pattern, as seen with CWD in deer and elk, across all passages.
Therefore, all pathological, biochemical, and histological strain characteristics of CWD appear to persist upon
repetitive serial passage through mice. These findings indicate that the salient strain-specific properties of
CWD are encoded by agent-intrinsic components rather than by host factors.
Mammalian prion diseases are believed to be caused by the
misfolding of a host-encoded cellular protein, PrPC, into an
aggregated, beta-sheet-rich, insoluble isoform, PrPSc, which
self-propagates and leads to fatal neurodegeneration (25, 38).
Insoluble PrPSc aggregates are detectable in the central ner-
vous system and skeletal muscle and also throughout the lym-
phoid system in a subset of diseases, including variant (22, 47)
and sporadic (19) Creutzfeldt-Jakob disease in humans, scrapie in
sheep and goats (21), and chronic wasting disease (CWD) in
cervids (34, 43).
CWD is a geographically widespread and locally prevalent
prion disease of North American cervids. CWD occurs natu-
rally in wild and captive mule deer, white-tailed deer, Rocky
Mountain elk (51), and wild moose (M. W. Miller, unpublished
data). The origins of CWD and its relationship to other prion
diseases remain uncertain (33). Mouse-adapted prion strains
of sheep scrapie and bovine spongiform encephalopathy (BSE)
have proven very useful for studying and comparing prion
strain properties (7, 28) and for understanding the peripheral
pathogenesis of prion disease (11, 23, 29, 30, 37). However, the
transmission of CWD to wild-type mice is inefficient (12) in
contrast to transgenic mice expressing the deer or elk PrP
sequences (4, 12, 24). This suggests that a species barrier exists
between cervids and mice. Here we used a transgenic mouse
model that overexpresses murine PrP to develop a murine-
adapted CWD strain of prion. We report that this strain in-
duces a unique histopathological phenotype and displays bio-
chemical and biophysical properties similar to those of deer
CWD but distinct from those of a Rocky Mountain Laboratory
(RML) strain of mouse-adapted scrapie. These strain-specific
properties were stable over three generations of serial trans-
mission in mice. These newly generated murine CWD prions
provide a tool for further studying the biophysical nature of
prion strains, e.g., by identifying differential PrPSc-interacting
proteins.
MATERIALS AND METHODS
Tga20 mice and prion infection. Transgenic mice overexpressing murine PrP
(17) were intracerebrally inoculated in the left parietal cortex with 30 l of a 10%
brain homogenate (5% for subsequent passages) from a terminal, CWD-infected
mule deer or an uninfected control deer (mock). Mice were monitored every
second day, and scrapie was diagnosed according to clinical criteria, including
ataxia, kyphosis, and hind leg paresis. Mice were sacrificed at the onset of
terminal disease. Mice were maintained under specific pathogen-free conditions,
and all experiments were performed in accordance with the animal welfare
guidelines of the Kanton of Zu¨rich.
Histochemical and immunohistochemical stains. Tissues were fixed in 4%
buffered formalin, treated with 98% formic acid for 1 h, and postfixed for 24 h
prior to paraffin embedding. Two-micrometer-thick sections were cut on posi-
tively charged glass slides and stained with hematoxylin and eosin or immuno-
stained using antibodies for PrP (SAF84), astrocytes (glial fibrillary acidic pro-
tein [GFAP]), or microglia (Iba1). For PrP staining, sections were deparaffinized
and incubated for 6 min in 98% formic acid and then washed in distilled water
for 5 min. Sections were heated to 100°C in citrate buffer (pH 6.0), cooled for 3
min, and then washed in distilled water for 5 min. Immunohistochemical stains
were performed on an automated Nexus staining apparatus (Ventana Medical
Systems) using an IVIEW DAB detection kit (Ventana). After incubation with
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protease 1 (Ventana) for 16 min, sections were incubated with anti-PrP SAF-84
(SPI bio; 1:200) for 32 min. Sections were counterstained with hematoxylin.
GFAP immunohistochemistry for astrocytes (1:1,000 for 24 min; DAKO) and
Iba1 (1:2,500 for 32 min; Wako Chemicals) for microglia were similarly per-
formed, however, with antigen retrieval by heating to 100°C in EDTA buffer (pH
8.0). Histoblot analyses were performed as previously described (45).
For thioflavin T and Congo red staining, frozen brain sections were fixed in
70% ethanol for 10 min. For thioflavin staining, sections were immersed in 1%
thioflavin T for 3 min, followed by 1% acetic acid for 10 min and then distilled
water for 5 min. For Congo red staining, slides were immersed in an alkaline
solution and then stained with Congo red solution for 20 min.
Lesion profile. Twelve anatomic brain regions were selected in accordance
with previous strain typing analysis protocols (13, 18) by using three to five mice
per passage. Spongiosis was evaluated on a scale of 0 to 5 (not detectable, mild,
moderate, severe, and status spongiosis). Gliosis and PrPSc content were scored
on a scale of 0 to 3 (not detectable, mild, moderate, and severe). A sum of the
three scores resulted in the value that was employed in order to obtain the lesion
profile for the individual animal. Histological analysis was performed by inde-
pendent investigators blinded to animal identification.
Ultrastructural characterization. Small samples (1 mm3) were retrieved from
formalin-fixed, paraffin-embedded blocks and reversed to electron microscopy as
previously described (3). Grids stained with lead citrate and uranyl acetate were
observed and photographed with a JEM 100C transmission electron microscope
at 80 kV.
Western blots. Ten-percent brain or spleen homogenates were prepared in
phosphate-buffered saline using a ribolyzer, and 80 to 90 g protein was diluted
with Tris lysis buffer (10 mM Tris, 10 mM EDTA, 100 mM NaCl, 0.5% NP-40,
and 0.5% deoxycholate) and digested with 100 g/ml proteinase K for 30 min at
37°C. Sodium dodecyl sulfate-based loading buffer was then added, and samples
were heated at 95°C for 5 min prior to electrophoresis through a 12% Bis-Tris
precast gel (Invitrogen), followed by transfer to a nitrocellulose membrane by
wet blotting. Proteins were detected with the following panel of “POM” anti-PrP
antibodies (36): POM1 (epitope amino acids [aa] 121 to 230), POM2 (epitope aa
58 to 64, 66 to 72, 74 to 80, and 82 to 88), POM3 (epitope aa 95 to 100), and
POM11 (epitope aa 64 to 72 and 72 to 80). Signals were visualized with an ECL
detection kit (Pierce).
RESULTS
Incubation period and clinical disease. tga20 transgenic
mice overexpress mouse PrP owing to a Prnp-encoding vector
known as the “half-genomic construct,” which is based on a
murine PrP minigene lacking intron 2 (17). tga20 mice were
inoculated intracerebrally with CWD from a terminally in-
fected mule deer. All inoculated mice developed neurologic
disease with an incubation period (IP) of 500  62 (range, 408
to 521) days postinoculation (Fig. 1A). Remarkably, the clini-
cal attack rate was 100% (10/10). This contrasts with the poor
infectibility of wild-type mice with CWD and may be attributed
to the higher PrPC expression levels in tga20 mice.
To determine whether the new murine CWD strain would
adapt further in the mouse, we performed a second passage of
CWD. This was accomplished by injecting brain homogenate
from CWD-infected, terminally sick mice into another group
of tga20 mice. The second passage led to an abbreviated IP:
mice developed terminal disease with an IP of 228  103 dpi
(range, 139 to 438) (Fig. 1B). By the third passage, the incu-
bation period dropped to 162 days, with little variability among
the mice (6 days) (Fig. 1C). In contrast, tga20 mice inocu-
lated with 3  103 50% lethal dose units of RML scrapie
developed terminal neurologic disease after 74 days (5 days)
(Fig. 1C).
Clinical signs were similar among mice receiving primary
deer CWD and murine-adapted CWD and included kyphosis,
ataxia, tremors, and intense pruritus (Fig. 2 and see the sup-
plemental material). CWD-infected mice often showed a clin-
ical phenotype of obsessive pruritus. Mice continued scratch-
ing, even with palliative care of open abrasions, making
euthanasia unavoidable. Exogenous causes of ulceration were
not evident in the skin; no ectoparasites or other infectious
agents were observed.
Genetic and structural considerations. The prion sequence
of the mule deer was compared to that from mouse. When
comparing the sequences from residues 23 to 231, there was a
90.2% sequence homology between the deer and the mouse
(Fig. 2B). A comparison of the three-dimensional structures of
the elk and mouse prion proteins shows that both proteins
have the same globular fold, consisting of a flexibly disordered
domain of 100 residues and a C-terminal domain of similar
size, with three -helices and a short antiparallel -sheet (20).
FIG. 1. Survival of tga20 PrP-overexpressing mice challenged with
CWD prions. (A) First passage of mule deer CWD performed on two
separate occasions shows similar survival curves. Four mice were used
for subpassage into additional tga20 mice (indicated by , , , and 	).
Mock-inoculated mice were periodically sacrificed at the time points
indicated. (B) Second passage of CWD-infected brains from four mice.
Mouse ε was used for the third subpassage. (C) Third passage of CWD.
An RML scrapie survival curve is shown for comparison.
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However, the loop region that connects the second  strand
with the second -helix is very precisely defined in the elk prion
protein but disordered in mouse PrPC (Fig. 2C and D). Elk and
mule deer amino acid sequences are identical at this loop
region.
Disease phenotype and lesion profiles. We performed a de-
tailed investigation of the histopathologic lesions in each of the
serial passages of CWD (Fig. 3A). Spongiform lesions were
most prominent in the neuopil of thalamus, hippocampus, and
basal ganglia. Some cases also displayed extensive damage to
the cerebral cortex and the white matter tracts. Lesions ap-
peared to acquire greater severity with each serial passage
(Fig. 3A). By the third passage, mice developed a subtotal
elective loss of cerebellar granular cells, a finding absent in the
first and second passages (Fig. 3B). Astrogliosis and microglial
activation were often severe and regionally extensive in CWD-
infected mice (Fig. 3A). The findings described above were
quantified using a standardized lesion-profiling methodology
(35) and indicated that the severity of spongiform degenera-
tion, astrogliosis, and PrPSc deposition increased with each
serial passage (Fig. 3C). Some mock-inoculated animals had
mild-to-moderate vacuolization of white matter tracts, but no
neuronal loss or extensive astrogliosis, microgliosis, or plaques.
Four of nine (44%) first-passage, CWD-inoculated mice had
multiple large (50- to 300-m) plaques visible in the hematox-
ylin-and-eosin-stained sections, which immunolabeled for PrP.
Plaques appeared in the basal ganglia, thalamus, and hip-
pocampus and separated white matter fiber tracts in the corpus
callosum and cerebellum. Extensive plaques are not a feature
of RML mouse scrapie (A. Aguzzi and C. J. Sigurdson, un-
published data) but are common with cervid CWD (5, 44).
Remarkably, PrP plaques and deposits were often perivascular
(Fig. 3D) as in CWD in deer and elk but were also within vessel
walls. However, a subset of mice developed only small, diffuse
PrP deposits typical of RML mouse scrapie or developed
both plaques and diffuse deposits (Fig. 4A). Third passage of
the “plaque” strain led to plaque formation in all infected
mice. Plaques were composed of dense deposits similar to
those seen with the first passage.
Plaque structure. By light microscopy, murine CWD
plaques were composed of fiber bundles emanating from a
dense core in stellate arrangement and were unicentric or
multicentric. Thioflavin T positivity and Congo red birefrin-
gence indicated that the plaques had a highly organized amy-
loid fibril cross- fold structure (Fig. 4B). By electron micros-
copy, plaques were composed of compact amyloid bundles and
appeared as subpial (Fig. 5A), unicentric (Fig. 5B and E), or
perivascular deposits (Fig. 5D). Overall, the morphologies of
plaques recapitulated that observed in mule deer with CWD
(27) and were similar to the human prion disease Gerstmann-
Straussler-Scheinker disease (GSS). As with GSS, microglial
cells were in close contact with the amyloid bundles (Fig. 5C)
(6, 26).
Histoblot analysis. To visualize proteinase K (PK)-resistant
PrPSc in brain and spleen, we performed histoblot analyses of
frozen tissue sections pressed onto nitrocellulose, proteinase K
treated, and labeled with anti-PrP antibodies. Here again we
found abundant PrPSc plaques and diffuse deposits in the brain
in a pattern that varied from those of RML mice (Fig. 6A).
Mice inoculated with second and third passages of the “plaque”
strain developed PrPSc deposits in the spleen in follicular patterns
similar to those of RML-infected mice (Fig. 6B).
Biochemical profile of murine CWD. We analyzed protein-
ase K-resistant PrPSc in brain infected with murine CWD by
Western blotting and compared it with that of a standard
murine RML scrapie isolate and with that of CWD in deer. We
found that CWD in deer was characterized by a predominant
diglycosylated isoform of PrPSc as described previously (39). In
contrast, RML murine scrapie presents with a dominant mono-
glycosylated PrPSc isoform. In most CWD-infected mice with
the “plaque” strain, the diglycosylate-rich glycoform pattern
was faithfully propagated. However, two of seven mice devel-
oped nearly equal levels of di- and monoglycosylated isoforms
on the third passage (Fig. 7). Murine first-passage strains of
sheep scrapie and BSE (also in tga20) showed glycoform ratios
similar to that found with the third passage of murine CWD
(Fig. 7). The PK cutting site in murine CWD was then defined
by differential antibody immunoreactivity of PrP27
30 to be
between amino acids 73 to 82, as POM11 (epitope aa 64 to 72
and 72 to 80) did not recognize PrP27
30 (data not shown).
FIG. 2. Clinical signs, genetics, and structural biology of murine
CWD. (A) Mice with clinical signs of CWD are characterized by
kyphosis, pruritus, ataxia, and tremors in contrast to mice with RML
scrapie which are primarily ataxic with stiff tails (arrowhead). The
CWD-infected mouse is scratching (arrow indicates skin abrasion).
(B) A PrP gene sequence alignment for the mouse and mule deer
shows 90.2% homology. Amino acids are color coded as follows: red,
small and hydrophobic; blue, acidic; magenta, basic; green, hydroxyl
and amine and basic. (C and D) Superposition of the mean nuclear
magnetic resonance (NMR) structures of the polypeptide segment of
aa 125 to 229 (C) and 165 to 172 (D) in ePrP(121-230) (red) and
mPrP(121-230) (blue). A spline function was drawn through the C
positions. The radius of the cylindrical rods representing the polypep-
tide chains is proportional to the mean backbone displacement per
residue (XX), as evaluated after superposition for best fit of the atoms
N, C, and C in the 20 energy-minimized conformers used to repre-
sent the NMR structures (9). The PrP structure from the CWD source
deer used herein may vary slightly from the elk.
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FIG. 3. Histopathology and PrPSc plaques in CWD-infected mice. (A) Brain at hippocampus. PrP plaques are visible in hematoxylin and
eosin (HE) stains and by immunohistochemical labeling for PrP, particularly in the corpus callosum. Extensive astrocytosis and microglial
activation is evident. Note the increased severity of gliosis, microglial activation, and plaque deposition with each passage. Bar  200 m.
(B) Severe degeneration with massive loss of the cerebellar granular cells occurred by the third passage. Bar  200 m or 20 m. (C) Lesion
profile of CWD infected mice, comparing first through third passage. Profile scores are determined by spongiform change, gliosis, and PrPSc
deposits in the specific brain regions indicated. (D) Vascular plaques in meninges and brain parenchyma of CWD-infected mice. Bar 
50 m.
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DISCUSSION
Prion transmission between species is often inefficient and
goes along with prolonged incubation periods. However, serial
passages within the new species often lead to a shortening of
the incubation period (48), a phenomenon that has been
termed adaptation. Neither the molecular underpinnings of
the species barrier nor those of prion adaptation are fully
understood. The primary amino acid sequence of host PrPC
clearly contributes to the species barrier effect (40, 50), yet
additional factors intrinsic to the infectious agent, be they
PrPSc conformation, PrPSc aggregational state, and/or ancillary
molecules (49), also affect susceptibility and disease phenotype
(15, 16, 46). Because of such agent-autonomous factors, spe-
cies barriers are specified by the pathogenic prions in addition
to the genotype of the hosts: bovine spongiform encephalop-
athy is, e.g., readily transmissible to species that are hardly
susceptible to sheep scrapie (32).
Although Prnp is very well conserved among most species,
the mouse and deer PrP amino acid sequences are relatively
divergent. Amino acid identity is only 90.2% between residues
23 to 231, and the respective PrPC structures strikingly diverge
between amino acids 165 to 172 (20). This finding may underlie
the inefficient CWD prion conversion in wild-type mice. How-
ever, even a high degree of homology between PrP molecules
is not predictive for efficient conversion, as single-amino-acid
substitutions can create a strong species barrier (31).
Despite the structural constraints listed above, we found that
overexpression of murine PrP of four- to sixfold sufficed to
enable the efficient transmission of deer CWD to mice. This
was unexpected since the expression levels of Prnp were not
found to be rate limiting for ecotropic prion replication in
other systems (14). In contrast, these findings suggest that host
PrPC expression levels may significantly affect the robustness of
species barriers.
CWD manifested itself in tga20 mice with features that are
remarkably similar to those of CWD in deer and strikingly
different from those of the commonly used RML strain of
mouse-adapted sheep prions. Some CWD-infected mice devel-
oped very large multicentric extracellular amyloid plaques that
were intensely stained by thioflavin and Congo red, often po-
FIG. 4. Plaque characterization in CWD-infected mice. (A) PrPSc deposits vary from small, diffuse aggregates to dense plaques, often occurring
as a mixture of both deposit types. Bar  50 m. (B) Plaques were thioflavin positive and showed birefringence after Congo red staining indicative
of amyloid formation. Bar  20 m.
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sitioned within white matter tracts or around vessels, similar to
those described for deer with CWD (44) and for humans with
GSS (26). In contrast, plaques were never seen in RML-in-
fected tga20 mice or RML-infected wild-type C57BL/6 inbred,
129Sv inbred, or C57BL/6  129Sv crossbred mice (A. Aguzzi,
unpublished data).
The plaques were reminiscent of those shown by Scott et al.
in mice expressing bovine PrP and challenged with BSE or
sheep scrapie prions (41). In mice with plaques, the plaque
phenotype was stable and persisted even after the third serial
passage of CWD in mice.
The second passage of CWD in the tga20 mice revealed
broadly divergent disease phenotypes. First, the plaque phe-
notype was not present in all second-passage mice, as a subset
of four mice (inoculated with isolates from a mouse that did
not have plaques) developed only diffuse granular PrP stain
deposits as seen by immunohistochemistry, and PrPSc signals in
the brain by Western blotting was low. Second, one group of
FIG. 5. Ultrastructural analysis of murine CWD plaques. (A) Subpial deposits were composed of numerous unicentric plaques. Magnification,
2,000. (B) Unicentric kuru-like plaque. Magnification, 6,000. (C) A plaque margin showing microglial cells. Amyloid bundles are in close
contact with the cell (arrow). Magnification, 13,000. (D) Perivascular plaque. The nucleus (arrow) and cytoplasm (arrowhead) of the pericyte is
visible. Magnification, 8,300. (E) Unicentric plaque. Magnification, 8,300. (F) High-power view of separate amyloid bundles. Magnification,
20,000.
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second-passage mice developed disease after a remarkably long
incubation period. Third, there was also an inconsistent detection
of splenic PrPSc in the second-passage mice. These findings sug-
gest that there may be multiple CWD strains present in the deer,
with each maintaining a presence in the tga20 mice. Alternatively,
it is also possible that the variability is intrinsically linked to the
mechanism of strain adaptation, with the strain phenotype diver-
sifying as a process of the adaptation.
We considered the possibility that the above variability may
have resulted from the contamination of the inoculum with our
FIG. 6. Histoblots of brain and spleen reveal differences in neural PrPSc distribution in murine CWD (overall less PrPSc) compared to RML mouse scrapie.
Abundant PrPSc deposits were present in spleen of some CWD-infected mice. No PrPSc stain was seen in the mock-inoculated mouse. Bar  500 m.
FIG. 7. Biochemical characterization of PrPSc in murine CWD (A and B). Western blots and triplot of murine CWD-infected brain showing a predominant
diglycosylated band in most mice on first passage. By the third passage, the glycoform pattern shifted slightly with an increase in the monoglycosylated PrP and
was similar to deer CWD, murine BSE, and murine sheep scrapie, but unlike the mouse-adapted RML. 
, absence of; , presence of.
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RML laboratory strain. This, however, is extremely unlikely, as
the incubation periods for RML are much shorter than those
reported here. When exposed to limiting infectious doses of
RML, tga20 mice consistently develop disease in 180 days
(10, 42) or resist infection completely. In addition, the clinical
signs for RML differ strikingly from those detected with mu-
rine CWD. Finally, the time lag between the first clinical signs
and terminal disease is only a few days in RML-infected tga20
mice, whereas it extended over weeks in CWD-infected mice.
Clues to prion strain differences lie in the conformational
state of the misfolded prion protein and in the ratio of the PrP
glycoforms (7, 8). Several techniques were employed to explore
these features, including the quantitation of the relative pro-
portion of the three glycoforms by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and determination of the
proteinase K cleavage site (8) with a panel of anti-PrP anti-
bodies recognizing various epitopes amino- and carboxy-prox-
imal to the putative cleavage site (36, 53). We found that the
murine CWD glycoform profile shifted slightly with serial pas-
sage from a highly abundant diglycosylated PrPSc on first pas-
sage to an almost equal ratio of di- and monoglycosylated
PrPSc by the third passage, a ratio which was close to that of
CWD in deer, murine BSE, and murine sheep scrapie and
varied from that of RML. The PK cleavage site was assessed in
the third passage of murine CWD and localized to amino acids
73 to 82. This is consistent with the PK-cutting sites for elk
CWD at Gly78 and Gly82 (52) and suggests that features of the
CWD PrPSc structure are maintained in the mouse.
CWD prions were serially passaged three times. With each
passage, the incubation period decreased and the brain lesions
and PrP plaques developed to a greater severity. This is con-
sistent with other instances of strain adaptation, in which prion
virulence tended to increase with time. However, the biochem-
ical, the histopathological, and even the clinical characteristics
of the disease remained remarkably constant, suggesting that
the phenotype-specifying information is enciphered more
within the agent rather than in the host. The stability of the
phenotypic traits over three passages suggests that the pheno-
type-specifying information undergoes replication along with
the infectious principle.
Within the framework of the protein-only hypothesis, the
above phenomenon might be explained by postulating that
CWD prions possess a particular steric conformation that is
unique, distinct from that of RML scrapie prions, and capable
of imparting the same conformation onto mouse PrPC, which
will then propagate this unique conformation indefinitely upon
serial passage (1).
Alternatively, PrPSc aggregates derived from CWD-infected
deer may be packed in a specific quaternary assembly state that
grows appositionally in a growth pattern similar to that of a
crystal. Such quasicrystals might be shaped differently from
RML aggregates and might incorporate murine PrPSc upon
passaging to mice (2). Eventually, repeated serial passages
would lead to the propagation of an aggregated moiety that
consists exclusively of murine PrPSc but retains the unique
quaternary structure of CWD prions.
A further model predicates that conventional replicative
molecules, such as DNA, RNA, or micro-RNA, might be in-
corporated into PrPSc. While prion infectivity is solely specified
by PrPSc (the “apoprion”), the strain-specific characteristics
would be propagated by such “coprions” (49).
Finally, CWD prions may incorporate specific subsets of
host molecules, be they proteins, lipids, nucleic acids, or other
constituents, according to a unique stoichiometry. Prion repli-
cation upon cross-species passage might reproduce this stoi-
chiometry, thereby preserving the strain-specific traits. The
propagation of a well-characterized strain of CWD prions
within genetically homogeneous hosts yields a powerful tool
for testing each of the above hypotheses. A particularly prom-
ising avenue of future work consists of utilizing contemporary
proteomic tools, such as differential mass spectrometry with
isotope-coded affinity tags, to enumerate non-PrPSc compo-
nents that are associated with mouse-passaged CWD prions
and may contribute to their unique phenotypic traits.
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